Accrual Delayed in Adjuvant Bevacizumab Trial
Open Access
- 5 April 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 98 (7) , 439-440
- https://doi.org/10.1093/jnci/djj148
Abstract
Researchers have temporarily halted accrual to a trial of bevacizumab (Avastin) and two chemotherapy regimens for early-stage colon cancer after they found an unexpected number of non-cancer-related deaths in one of the study arms. The data safety monitoring board (DSMB) recommended that enrollment be delayed until 60-day mortality data could be collected and reviewed for all patients currently in the study. Experts say that the imbalance in deaths is likely to be a statistical anomaly, but they agree that the safety committee acted appropriately.Keywords
This publication has 0 references indexed in Scilit: